News archive
- February 17, 2023InformationNEW
- Feb 9: Our founding director, Prof. Hiroaki Suga at the University of Tokyo, has been awarded the prestigious 2023 Wolf Prize in Chemistry.
- December 6, 2022InformationNEW
- Nov 24: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was introduced in the Nature biomedical engineering, “news & views” (Nat Biomed Eng, 24 Nov (2022). https://www.nature.com/articles/s41551-022-00974-3).
- November 9, 2022Information
- Nov 8: A paper on Lassograft Technology by Associate Prof. Katsuya Sakai, Kanazawa University, Prof. Kunio Mastumoto, Kanazawa University, Prof. Junichi Takagi, Osaka University and Prof. Hiroaki Suga, University of Tokyo was published in the Nature biomedical engineering (Nat Biomed Eng, 07 Nov (2022). https://doi.org/10.1038/s41551-022-00955-6).
- August 10, 2021Information
- Aug 10: Our Company entered into a drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. (TSE First Section: Securities Code 4528) to create next-generation biopharmaceuticals using our proprietary LassoGraft Technology that integrates cyclic peptide discovery method (RaPID System) with protein engineering (PDF attached).
- March 10, 2021Information
- Mar 9: A paper on Lassograft Technology by Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo was published in the Nature Communications (Nature Commun 12, 1543 (2021). https://doi.org/10.1038/s41467-021-21875-0).
- November 26, 2020Information
- Nov 20: A paper on Lassograft Technology by Prof. Junichi Takagi, Osaka University, and Prof. Hiroaki Suga, University of Tokyo, was published in the Preprint (a Nature Research journal).
- June 29, 2020Information
- Jun 29: Our company has been selected for NEDO’s (New Energy and Industrial Technology Development Organization) FY2020 “Research and Development Venture Support Program / Commercialization Support for Research and Development Ventures at Seed Stage”. The title of the grant is “Verification of the Pharmaceutical Properties of Met Agonists for the Treatment of NASH” and we will promote our own development project.
- January 27, 2020Information
- Feb 8 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 2).
- January 27, 2020Information
- Feb 1 [Japanese Only] President Kato appeared at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)”, introduced our business (Part 1).
- January 17, 2020Information
- Jan. 15: Notice Concerning Third Party Allocation ／ In order to further accelerate the business, MiraBiologics Inc. announces the completion of 550 million Japanese Yen (US$ 5 Million, as of Jan. 10, 2020) private financing, led by Shinsei Capital Partners Ltd. as a lead investor, and , SMBC Venture Capital Co., Ltd, SBI Investment Co., Ltd.